An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: Design, rationale, and methods of the initio trial

Controlled Clinical Trials

Volumn 22, Issue 2, 2001, Pages 160-175

  Babiker, A G ^a   Darbyshire, J H ^a   Cooper, D A ^a   Hooker, M H ^a   Withnall, R ^a   Yeni, P ^a   Angarano, G ^a   Antunes, F ^a   Churchill, D ^a   Conway, B ^a   Flepp, M ^a   Lelekis, M ^a   Gatell, J ^a   Girard, P M ^a   Hemmer, R ^a   Lundgren, J ^a   Mijch, A ^a   Mulcahy, F ^a   Ristola, M ^a   Salzberger, B ^a   Sandstrom E ^a   Staszewski, S ^a   Weber, J ^a   De Wit, S ^a   Aboulker, J P ^a   Emery, S ^a   Floridia, M ^a   Gartland, M ^a   Manion, D ^a   Popescu, M ^a   Schnittman, S ^a   Stek, M ^a   Verbiest, W ^a   Flandre, P ^a   Law, M ^a   Schade Brittinger, C ^a   Walker, S ^a   Bucciardini, R ^a   Boukli, N ^a   Carey, D ^a   Gargalianos, P ^a   Mollerup, D ^a   Brun Vezinet, F ^a   Loveday, C ^a   Seligmann, M ^a   more..

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Antiretroviral therapy; HIV infection; Initial treatment; Randomized trial

Indexed keywords

ABACAVIR; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADULT; DIDANOSINE; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NELFINAVIR; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RITONAVIR; SAMPLE SIZE; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

EID: 0035071409     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(00)00123-9     Document Type: Article

References (23)

1. Changing patterns of mortality across Europe in patients infected with HIV. The EuroSIDA study
2. Survival after introduction of HAART in people with known duration of HIV infection
3. Residual pool of HIV after prolonged combination therapy
4. 6/I CD4 cells treated with highly active antiretroviral therapy
5. Longer follow-up in the Delta trial: Does initial antiretroviral regimen matter in the long term?
6. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
7. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cells counts from 200 to 500 per cubic millimeter
8. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter
9. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 counts of 200 per cubic millimeter or less
10. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
11. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
12. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
13. Outcomes of triple therapy that included a protease inhibitor among 2139 patients
14. Maintaining protease inhibitor therapy in a clinic setting
15. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
16. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: Meta-analyses of the randomised evidence
17. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine containing regimens for patients with HIV-1 infection: The CAESAR trial
18. ALBI (ANRS 070): A randomised controlled trial to evaluate the efficacy and safety of AZT/3TC versus alternating d4T/ddI and AZT/3TC versus d4T/ddI in treatment naïve HIV-infected patients
19. Update on efficacy and durability of ritonavir/saquinavir as salvage therapy after failure of first protease inhibitor regimen
20. Virologic responses to a ritonavir/saquinavir containing regimen in patients who have previously failed nelfinavir
21. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome
22. HIV-1 RNA level and CD4 count as prognostic markers and surrogate endpoints - A systematic overview
23. Prognosis in HIV-1 infection predicted by the quantity of virus in the plasma